Publications
5491 Results
- Journal / Conference
- Clinical Cancer Research Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26.
- Year
- 2021
- Research Committee(s)
- Genitourinary
- PMID
- PMID33500355
- PMC
- PMC8026618
- Study Number(s)
- S1216
Baseline circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (SWOG S1216)
- Journal / Conference
- Journal for Immunotherapy of Cancer May;9(5):e002535. doi: 10.1136/jitc-2021-002535
- Year
- 2021
- Research Committee(s)
- Melanoma
- PMID
- PMID33963015
- PMC
- PMC8108687
- Study Number(s)
- CTSU/E1609
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Journal / Conference
- JNCI Cancer Spectrum Feb 8;5(2):pkab018. doi: 10.1093/jncics/pkab018. eCollection 2021 Apr
- Year
- 2021
- Research Committee(s)
- Symptom Control and Quality of Life
- PMID
- PMID33842832
- PMC
- PMC8023424
- Study Number(s)
- S1202
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
- Journal / Conference
- Clinical Lung Cancer Jul;22(4):313-323
- Year
- 2021
- Research Committee(s)
- Lung
- PMID
- PMID33745865
- Study Number(s)
- S1206 (8811)
A dose-finding study followed by a phase II randomized, placebo-controlled trial of chemoradiotherapy with or without veliparib in stage III non-small cell lung cancer: SWOG S1206 (8811)
- Journal / Conference
- BMC Cancer Mar 26;21(1):324. doi: 10.1186/s12885-021-08050-w
- Year
- 2021
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID33771105
- PMC
- PMC7995697
- Study Number(s)
- S0528, S0711
Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
- Journal / Conference
- Contemporary Clinical Trials Apr 8;22:100768. doi: 10.1016/j.conctc.2021.100768. eCollection 2021 Jun.
- Year
- 2021
- Research Committee(s)
- Palliative and End of Life Care
- PMID
- PMID33997460
- PMC
- PMC8105629
- Study Number(s)
- S1820
SWOG S1820: Altering Intake, Managing Symptoms for Bowel Dysfunction in Survivors of Rectal Cancer (The AIMS-RC Intervention Trial)
- Journal / Conference
- Journal of the American Medical Association Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454.
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID33821899
- PMC
- PMC8025124
- Study Number(s)
- CTSU/C80702
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial
- Journal / Conference
- Journal of Clinical Oncology Aug 1;39(22):2486-2496; May 14;JCO2100286. doi: 10.1200/JCO.21.00286. Online ahead of print
- Year
- 2021
- Research Committee(s)
- Genitourinary
- PMID
- PMID33989025
- Study Number(s)
- CTSU/C90601
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
- Journal / Conference
- Annals of Oncology, Oct;32(10):1267-1275
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID34293461
- Study Number(s)
- CTSU/C80702
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)
- Journal / Conference
- JCO Oncology Practice Jul;17(7):e908-e916; Apr 26;OP2000990. doi: 10.1200/OP.20.00990. Online ahead of print
- Year
- 2021
- PMID
- PMID33900801
- PMC
- PMC8462669